Brief: Caladrius Biosciences Announces Idmc Recommendation To Advance Clbs201 Trial For Treatment Of Diabetic Kidney Disease
19/05/2022 15:36
Caladrius Biosciences Inc CLBS.O :
* CALADRIUS BIOSCIENCES ANNOUNCES IDMC RECOMMENDATION TO
ADVANCE
CLBS201 TRIAL FOR TREATMENT OF DIABETIC KIDNEY DISEASE
* CALADRIUS BIOSCIENCES INC - NO SAFETY OR TOLERABILITY
CONCERNS
OBSERVED IN FIRST TWO PATIENTS DOSED
* CALADRIUS BIOSCIENCES INC - TOP-LINE DATA FROM ALL
SUBJECTS
EXPECTED BY Q1 OF 2023
Source text for Eikon: ID:nGNX5Dtf7j
Further company coverage: CLBS.O
Recent news on Lisata Therapeutics
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Lisata Therapeutics Announces New Method Of Use Patent Granted For Certepetide In The Treatment Of Pancreatic Cancer And Other Solid Tumors
NASDAQ RESUMED AT 09:55 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
U.S. STOCKS ON THE MOVE -Expeditors International, Waters, Ameresco